Linee guida AIAC 2010 per la gestione e il trattamento della - Stopfa

al. Cardiac resynchronization in patients
with congestive heart failure and chronic
atrial fibrillation: effect of upgrading to
biventricular pacing after chronic right ventricular
pacing. J Am Coll Cardiol 2002;39:
1258-63.
676. Valls-Bertault V, Fatemi M, Gilard M,
Pennec PY, Etienne Y, Blanc JJ. Assessment
of upgrading to biventricular pacing in patients
with right ventricular pacing and congestive
heart failure after atrioventricular
junctional ablation for chronic atrial fibrillation.
Europace 2004;6:438-43.
677. Kamath GS, Cotiga D, Koneru JN, et
al. The utility of 12-lead Holter monitoring in
patients with permanent atrial fibrillation
for the identification of nonresponders after
cardiac resynchronization therapy. J Am Coll
Cardiol 2009;53:1050-5.
678. Gasparini M, Auricchio A, Regoli F, et
al. Four-year efficacy of cardiac resynchronization
therapy on exercise tolerance and
disease progression: the importance of performing
atrioventricular junction ablation in
patients with atrial fibrillation. J Am Coll
Cardiol 2006;48:734-43.
679. Ferreira AM, Adragao P, Cavaco DM,
et al. Benefit of cardiac resynchronization
therapy in atrial fibrillation patients vs patients
in sinus rhythm: the role of atrioventricular
junction ablation. Europace 2008;
10:809-15.
680. Koplan BA, Kaplan AJ, Weiner S, Jones
PW, Seth M, Christman SA. Heart failure
decompensation and all-cause mortality in
relation to percent biventricular pacing in
patients with heart failure: is a goal of
100% biventricular pacing necessary? J Am
Coll Cardiol 2009;53:355-60.
681. Khadjooi K, Foley PW, Chalil S, et al.
Long-term effects of cardiac resynchronisation
therapy in patients with atrial fibrillation.
Heart 2008;94:879-83.
682. Delnoy PP, Ottervanger JP, Luttikhuis
HO, et al. Comparison of usefulness of cardiac
resynchronization therapy in patients
with atrial fibrillation and heart failure versus
patients with sinus rhythm and heart
failure. Am J Cardiol 2007;99:1252-7.
683. Tolosana JM, Hernandez Madrid A,
Brugada J, et al.; SPARE Investigators. Comparison
of benefits and mortality in cardiac
resynchronization therapy in patients with
atrial fibrillation versus patients in sinus
rhythm (Results of the Spanish Atrial Fibrillation
and Resynchronization [SPARE] Study).
Am J Cardiol 2008;102:444-9.
684. Singer DE, Albers GW, Dalen JE, Go
AS, Halperin JL, Manning WJ. Antithrombotic
therapy in atrial fibrillation: the Seventh
ACCP Conference on Antithrombotic
and Thrombolytic Therapy. Chest 2004;
126(3 Suppl):429S-456S.
685. Di Pasquale G. Fibrillazione atriale e
stroke. Giornale Italiano di Aritmologia e
Cardiostimolazione 2001;4:149-61.
686. Emmerich J, Le Heuzey JY, Bath PM,
Connolly SJ. Indication for antithrombotic
LINEE GUIDA AIAC 2010 PER LA GESTIONE EIL TRATTAMENTO DELLA FA
therapy for atrial fibrillation: reconciling the
guidelines with clinical practice. Eur Heart J
Suppl 2005;7(Suppl C):C28-C33.
687. Gage BF, Waterman AD, Shannon W,
Boechler M, Rich MW, Radford MJ. Validation
of clinical classification schemes for predicting
stroke: results from the National Registry
of Atrial Fibrillation. JAMA 2001;285:
2864-70.
688. Wang TJ, Massaro JM, Levy D, et al. A
risk score for predicting stroke or death in individuals
with new-onset atrial fibrillation
in the community: the Framingham Heart
Study. JAMA 2003;290:1049-56.
689. Stroke Risk in Atrial Fibrillation Working
Group. Comparison of 12 risk stratification
schemes to predict stroke in patients
with nonvalvular atrial fibrillation. Stroke
2008;39:1901-10.
690. Stroke Risk in Atrial Fibrillation Working
Group. Independent predictors of stroke
in patients with atrial fibrillation: a systematic
review. Neurology 2007;69:546-54.
691. Di Pasquale G, Urbinati S, Pinelli G.
New echocardiographic markers of embolic
risk in atrial fibrillation. Cerebrovasc Dis
1995;5:315-22.
692. Hart RG, Pearce LA, McBride R, Rothbart
RM, Asinger RW. Factors associated
with ischemic stroke during aspirin therapy
in atrial fibrillation: analysis of 2012 participants
in the SPAF I-III clinical trials. The
Stroke Prevention in Atrial Fibrillation (SPAF)
Investigators. Stroke 1999;30:1223-9.
693. The Investigators of FASTER Study: Fibrillazione
Atriale Studio Transesofageo Emiliano-Romagnolo,
Italy. Transesophageal
echocardiographic correlates of prior thromboembolism
in non-valvular atrial fibrillation:
a multicentre study [abstract]. Eur
Heart J 1996;17(Suppl):442.
694. Hart RG, Pearce LA, Aguilar MI. Metaanalysis:
antithrombotic therapy to prevent
stroke in patients who have nonvalvular
atrial fibrillation. Ann Intern Med
2007;146:857-67.
695. Petersen P, Boysen G, Godtfredsen J,
Andersen ED, Andersen B. Placebo-controlled,
randomised trial of warfarin and aspirin
for prevention of thromboembolic
complications in chronic atrial fibrillation.
The Copenhagen AFASAK Study. Lancet
1989;1:175-9.
696. The Boston Area Anticoagulation Trial
for Atrial Fibrillation Investigators. The effect
of low-dose warfarin on the risk of stroke in
patients with nonrheumatic atrial fibrillation.
N Engl J Med 1990;323:1505-11.
697. Connolly SJ, Laupacis A, Gent M,
Roberts RS, Cairns JA, Joyner C. Canadian
Atrial Fibrillation Anticoagulation (CAFA)
study. J Am Coll Cardiol 1991;18:349-55.
698. Ezekowitz MD, Bridgers SL, James KE,
et al. Warfarin in the prevention of stroke associated
with nonrheumatic atrial fibrillation.
Veterans Affairs Stroke Prevention in
Nonrheumatic Atrial Fibrillation Investigators.
N Engl J Med 1992;327:1406-12.
699. European Atrial Fibrillation Trial (EAFT)
Study Group. Secondary prevention in nonrheumatic
atrial fibrillation after transient
ischaemic attack or minor stroke. Lancet
1993;342:1255-62.
700. Schulman S, Beyth RJ. Risk of bleeding
with long-term antithrombotic therapy in
atrial fibrillation. Eur Heart J Suppl 2005;7
(Suppl C):C34-C40.
701. Pisters R, Lane DA, Nieuwlaat R, de
Vos CB, Crijns HJ, Lip GY. A novel userfriendly
score (HAS-BLED) to assess one-year
risk of major bleeding in atrial fibrillation patients:
the Euro Heart Survey. Chest 2010;
138:1093-100.
702. Stroke Prevention in Atrial Fibrillation
Investigators. Adjusted-dose warfarin versus
low-intensity, fixed-dose warfarin plus
aspirin for high-risk patients with atrial fibrillation:
Stroke Prevention in Atrial Fibrillation
III randomised clinical trial. Lancet
1996;348:633-8.
703. Pengo V, Zasso A, Barbero F, et al. Effectiveness
of fixed minidose warfarin in the
prevention of thromboembolism and vascular
death in nonrheumatic atrial fibrillation.
Am J Cardiol 1998;82:433-7.
704. Gullov AL, Koefoed BG, Petersen P, et
al. Fixed minidose warfarin and aspirin alone
and in combination vs adjusted-dose warfarin
for stroke prevention in atrial fibrillation:
Second Copenhagen Atrial Fibrillation,
Aspirin, and Anticoagulation Study. Arch Intern
Med 1998;158:1513-21.
705. Hellemons BS, Langenberg M, Lodder
J, et al. Primary prevention of arterial thromboembolism
in non-rheumatic atrial fibrillation
in primary care: randomised controlled
trial comparing two intensities of coumarin
with aspirin. BMJ 1999;319:958-64.
706. Connolly S, Pogue J, Hart R, et al.;
ACTIVE Writing Group of the ACTIVE Investigators.
Clopidogrel plus aspirin versus
oral anticoagulation for atrial fibrillation in
the Atrial fibrillation Clopidogrel Trial with
Irbesartan for prevention of Vascular Events
(ACTIVE W): a randomised controlled trial.
Lancet 2006;367:1903-12.
707. de Denus S, Sanoski CA, Carlsson J,
Opolski G, Spinler SA. Rate vs rhythm control
in patients with atrial fibrillation: a metaanalysis.
Arch Intern Med 2005;165:258-
62.
708. Posada IS, Barriales V. Alternate-day
dosing of aspirin in atrial fibrillation. LASAF
Pilot Study Group. Am Heart J 1999;138(1
Pt 1):137-43.
709. Benavente O, Hart RG, Koudstal P,
Laupacis A, McBride R. Antiplatelet therapy
for preventing stroke in patients with nonvalvular
atrial fibrillation and no previous
history of stroke or transient ischemic attacks.
In: Warlow C, Van Gijn J, Sandercock
P, eds. Stroke module of the Cochrane database
of systematic reviews. London: BMJ
Publishing Group, 1999.
710. Stroke Prevention in Atrial Fibrillation
Investigators. Warfarin versus aspirin for pre-
G ITAL CARDIOL | VOL 12 | SUPPL 1 AL N 1 2011
67